Please assess the completion status of the following clinical trial:

Trial Title: Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age between 20 and 75 year-old~2. HBsAg-positive for \> 6 months apart (medical history can be alternative)~3. Currently being treated with entecavir 0.5 mg/day for more than 18 months~4. Undetectable HBV DNA in serum (\<20IU/mL) and HBeAg-negative or positive for \> 1year~5. HBsAg titer \< 3,000 IU/mL~6. ALT\<300 IU/L~7. Signed written informed consent after being instructed about the objective and procedure of the clinical study~Exclusion Criteria:~1. Patients with decompensated liver cirrhosis, any one of the following ① Serum bilirubin \> 3 mg/dL~   ② Prothrombin time \> 6 seconds prolonged or INR \>2.3~   ③ Serum albumin \< 2.8 g/dL~   ④ History of ascites, variceal hemorrhage, or hepatic encephalopathy~   ⑤ Child-Pugh score ≥7 (Child-Pugh class B or C)~2. Patients who have evidence of renal insufficiency defined as serum creatinine\>1.5 mg/dL~3. Patients with psychological problem including depression~4. Patients who have previous/current significant co-morbidities including congestive heart failure, chronic kidney disease, hematologic disease and malignancy including hepatocellular carcinoma(patients with malignancy cured 5 years before screening can be enrolled)~5. Patients with seropositivity for anti-HCV, anti-HDV or anti-HIV~6. Patients who have excessive alcohol consumption (\> 30 g/day)~7. Patients who have evidence of autoimmune hepatitis, hemochromatosis or Wilson's disease~8. Pregnant or breast feeding females or plan for pregnancy or no contraception~9. Patients with disease may deteriorate with interferon therapy(eg, autoimmune thyroiditis)~10. Patients who have an psoriasis~11. Patients who have history of antiviral-resistant HBV after previous treatment with oral antiviral agents~12. Previous diagnosis with immunodeficiency or concomitant treatment of immune suppressive agent or previous organ transplantation Recipients~13. Patients who have a history of hypersensitivity to study drug~14. Uncontrollable seizure, convulsion and/or central nervous system disorders~15. Patients with severe bone marrow disorder or with history of hypersensitivity to biologic agent such as vaccine.~16. Neutrophil count \< 1,500/mm3 or platelet count \< 75,000/mm3 or hemoglobin \< 10 g/dl~17. Patients with Pulmonary disease (in case of history of pulmonary disease with complete recovery, enrollment is on investigator's discretion)~18. Patients who have a fever ≥ 38 °C at the baseline~19. Patients who have a risk of febrile response or systemic reaction~20. Patients who the investigator deems inappropriate to participate in this study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Concomitant:Pegasys, Euvax B, Baracrude (Type: EXPERIMENTAL): * Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks~* HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks~* Continue Entecavir(0.5mg) for 100 weeks(once daily)
- Sequential:Pegasys, Euvax B, Baracrude (Type: EXPERIMENTAL): * Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks~* HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks~* Continue Entecavir(0.5mg) for 100 weeks(once daily)
- Control Group (Type: ACTIVE_COMPARATOR): * Continue Entecavir(0.5mg) for 100 weeks(once daily)~* After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).